Influences on the pharmacokinetics of oxycodone: A multicentre cross-sectional study in 439 adult cancer patients

European Journal of Clinical Pharmacology

Volumn 67, Issue 5, 2011, Pages 493-506

  Andreassen, Trine Naalsund ^a   Klepstad, Pål ^a,b   Davies, Andrew ^c   Bjordal, Kristin ^d   Lundström, Staffan ^e   Kaasa, Stein ^a,b   Dale, Ola ^a,b,f  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e KAROLINSKA INSTITUTE   (Sweden)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Cancer population; Drug drug interactions; Metabolites; Oxycodone; Ratios; Serum concentrations

Indexed keywords

ALBUMIN; CYTOCHROME P450 3A4; DRUG METABOLITE; OXYCODONE;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CANCER PAIN; CANCER PATIENT; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

ANALGESICS, OPIOID; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MORPHINANS; NEOPLASMS; OXYCODONE; OXYMORPHONE; PAIN; SEX FACTORS;

EID: 79955642732     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0948-5     Document Type: Article

References (65)

1. Wilson KG, Max CH, Allard P, Chary S, Gagnon PR, Macmillan K, De LM, O'Shea F, Kuhl D, Fainsinger RL (2009) Prevalence and correlates of pain in the Canadian National Palliative Care Survey. Pain Res Manag 14(5):365-370
2. Holtan A, Aass N, Nordoy T, Haugen DF, Kaasa S, Mohr W, Kongsgaard UE (2007) Prevalence of pain in hospitalised cancer patients in Norway: a national survey. Palliat Med 21(1):7-13 (Pubitemid 47161276)
3. Van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18(9):1437-1449 (Pubitemid 47365475)
4. Klepstad P, Dale O, Kaasa S, Zahlsen K, Aamo T, Fayers P, Borchgrevink PC (2003) Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients. Acta Anaesthesiol Scand 47(6):725-731
5. McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA (1990) Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48(3):236-244 (Pubitemid 20323649)
6. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16(10):3222-3229 (Pubitemid 28481615)
7. American Pain Society (1999) Principles of analgesic use in the treatment of acute pain and cancer pain, 4th edn. American Pain Society, Glenview, IL
8. Leow KP, Smith MT, Williams B, Cramond T (1992) Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 52(5):487-495
9. Poyhia R, Seppala T, Olkkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33(6):617-621
10. Gourlay GK, Cherry DA, Cousins MJ (1986) A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25(3):297-312 (Pubitemid 16085474)
11. Sawe J (1986) High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 11(2):87-106
12. Hoskin PJ, Hanks GW, Aherne GW, Chapman D, Littleton P, Filshie J (1989) The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 27(4):499-505 (Pubitemid 19101158)
13. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD (1996) Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59(1):52-61 (Pubitemid 26048692)
14. Jannetto PJ, Bratanow NC (2009) Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics 10(7):1157-1167
15. Citron ML, Kaplan R, Parris WC, Croghan MK, Herbst LH, Rosenbluth RJ, Reder RF, Slagle NS, Buckley BJ, Kaiko RF (1998) Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. Cancer Invest 16(8):562-571 (Pubitemid 28541776)
16. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 2(3):239-249 (Pubitemid 28474354)
17. Moore KA, Ramcharitar V, Levine B, Fowler D (2003) Tentative identification of novel oxycodone metabolites in human urine. J Anal Toxicol 27(6):346-352 (Pubitemid 37022162)
18. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352(21):2211-2221
19. Guengerich FP (2005) Human cytochrome P450 enzymes. In: Ortiz de Montellano PR (ed) Cytochrome P450: structure, mechanism, and biochemistry, 3 edn. Kluwer Academic/Plenum, New York, p 424
20. Armstrong SC, Wynn GH, Sandson NB (2009) Pharmacokinetic drug interactions of synthetic opiate analgesics. Psychosomatics 50(2):169-176
21. Mertz D, Battegay M, Marzolini C, Mayr M (2009) Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. Am J Kidney Dis 54(1):E1-E4
22. Harris RZ, Benet LZ, Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50(2):222-239
23. Cotreau MM, von Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44(1):33-60 (Pubitemid 40100551)
24. Dorne JL, Walton K, Renwick AG (2003) Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol 41(2):201-224 (Pubitemid 35447872)
25. El Mouelhi M, Didolkar MS, Elias EG, Guengerich FP, Kauffman FC (1987) Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver. Cancer Res 47(2):460-466 (Pubitemid 17009609)
26. Yang LQ, Li SJ, Cao YF, Man XB, Yu WF, Wang HY, Wu MC (2003) Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 9(2):359-363
27. Kirchheiner J (2008) CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther 83(2):225-227
28. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369(1):23-37 (Pubitemid 38161221)
29. Richelson E (1997) Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 72(9):835-847
30. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32(3):210-258 (Pubitemid 27122521)
31. Davis MP, Homsi J (2001) The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 9(6):442-451 (Pubitemid 32843631)
32. Brosen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 60(4):312-314 (Pubitemid 17064154)
33. Ieiri I, Yamada S, Seto K, Morita T, Kaneda T, Mamiya K, Tashiro N, Higuchi S, Otsubo K (2003) A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. Pharmacopsychiatry 36 (5):192-196 (Pubitemid 37357367)
34. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160(4):907-918
35. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79(5):461-479
36. Kaiko RF (1997) Pharmacokinetics and pharmacodynamics of controlled-release opioids. Acta Anaesthesiol Scand 41(1 Pt 2): 166-174
37. Kirvela M, Lindgren L, Seppala T, Olkkola KT (1996) The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8(1):13-18 (Pubitemid 26068222)
38. Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L (1997) Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 61 (6):655-661 (Pubitemid 27279927)
39. Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Neuvonen M, Neuvonen PJ, Olkkola KT (2008) Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther 84(4):462-467
40. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71-87
41. Linares CL, Decleves X, Oppert JM, Basdevant A, Clement K, Bardin C, Scherrmann JM, Lepine JP, Bergmann JF, Mouly S (2009) Pharmacology of morphine in obese patients: clinical implications. Clin Pharmacokinet 48(10):635-651
42. Karnofsky, David A, Abelmann, Walther H, Craver, Lloyd F, Burchenal, Joseph H (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1(4):634-656
43. Drug Interactions: Cytochrome P450 Drug Interaction Table, January 12, 2009. http://medicine.iupui.edu/clinpharm/ddis/table.asp Accessed 3 August 2010
44. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, de Zeeuw D, Hostetter TH, Lameire N, Eknoyan G (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67(6):2089-2100 (Pubitemid 41623371)
45. Levey AS, Coresh J, Greene T, Marsh J, Kusek J, Van Lente Medicine F (2005) Estimating glomerular filtration rate with a new equation: MDRD4revised equation for use with IDMS-traceable serum creatinine. J Am Soc Nephrol 11[Suppl] :F-FC142
46. Green SB (1991) How many subjects does it take to do a regression analysis? Multivariate Behav Res 26(3):499-510
47. Miles J, Schevlin M (2001) Applying regression and correlation: a guide for students and researchers. Sage, Thousand Oaks, CA
48. Edwards SR, SmithMT (2007) Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 848(2):264-270
49. Dadgar D, Burnett PE, Choc MG, Gallicano K, Hooper JW (1995) Application issues in bioanalytical method validation, sample analysis and data reporting. J Pharm Biomed Anal 13 (2):89-97
50. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 16(4):249-255
51. Faura CC, Collins SL, Moore RA, McQuay HJ (1998) Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 74(1):43-53 (Pubitemid 28097728)
52. Hanna MH, D'Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S (1993) Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 70(5):511-514 (Pubitemid 23139509)
53. Peterson GM, Randall CT, Paterson J (1990) Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 38(2):121-124 (Pubitemid 20097314)
54. Pleym H, Spigset O, Kharasch ED, Dale O (2003) Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand 47(3):241-259 (Pubitemid 36384661)
55. Sarton E, Olofsen E, Romberg R, Den HJ, Kest B, Nieuwenhuijs D, Burm A, Teppema L, Dahan A (2000) Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology 93(5):1245-1254
56. Hunt CM, Westerkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44(2):275-283
57. Schmidt R, Baumann F, Hanschmann H, Geissler F, Preiss R (2001) Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(3):193-200 (Pubitemid 32988561)
58. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, ZangerUM(2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38(4):978-988 (Pubitemid 37221681)
59. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, Nurnberg P, Zanger UM, Wojnowski L (2007) Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 8(5):443-453 (Pubitemid 46746352)
60. Chen M, Ma L, Drusano GL, Bertino JS Jr, Nafziger AN (2006) Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 80(5):531-538 (Pubitemid 44737490)
61. George J, Byth K, Farrell GC (1995) Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 50(5):727-730
62. Williams ET, Leyk M, Wrighton SA, Davies PJ, Loose DS, Shipley GL, Strobel HW (2004) Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther 311(2):728-735 (Pubitemid 39391561)
63. Leow KP, Wright AW, Cramond T, Smith MT (1993) Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit 15 (5):440-447 (Pubitemid 23297249)
64. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA (2010) Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 160 (4):919-930
65. Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, Brosen K, Sindrup SH (2009) The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 104:335-344